Right, but with the cost distribution for clinical trials, costs increase by 4x in phase 2, then 8x in phase 3 (relative to phase 1).

So despite attrition that reduces candidates by 9x by phase 3, costs have increased by 8x.

[1]https://www.sofpromed.com/how-much-does-a-clinical-trial-cos...